BioMark Diagnostics Inc.
BMKDF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 1.16 | -0.60 | 0.38 |
| FCF Yield | -1.40% | -0.90% | -1.93% | -1.07% |
| EV / EBITDA | -88.86 | -105.21 | -116.53 | -69.32 |
| Quality | ||||
| ROIC | -44.77% | -23.11% | -20.61% | 58.14% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.00 | 0.69 | 1.07 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.00% | -0.52% | 0.16% | 3.99% |
| Free Cash Flow Growth | -70.49% | 36.48% | -138.60% | -45.32% |
| Safety | ||||
| Net Debt / EBITDA | 1.46 | -0.48 | 11.03 | -1.75 |
| Interest Coverage | -71.26 | -42.69 | -40.01 | -21.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,310.67 | 392.30 | 370.83 | 165.26 |